Clinical Trial Update: Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial of donor-derived CD5 CAR T cells (CT125B) for relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• CT125B CAR T cells (donor-derived CD5 CAR T)

Snippet

Sponsor: Beijing Boren Hospital | Conditions: T-Cell Acute Lymphoblastic Leukemia/Lymphoma | Phase 1 | Status: WITHDRAWN